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The importance of transdiagnostic
symptom level assessment to
understanding prognosis for depressed
adults: analysis of data from six randomised
control trials
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Abstract
Background: Depression is commonly perceived as a single underlying disease with a number of potential
treatment options. However, patients with major depression differ dramatically in their symptom presentation and
comorbidities, e.g. with anxiety disorders. There are also large variations in treatment outcomes and associations of
some anxiety comorbidities with poorer prognoses, but limited understanding as to why, and little information to
inform the clinical management of depression. There is a need to improve our understanding of depression,
incorporating anxiety comorbidity, and consider the association of a wide range of symptoms with treatment
outcomes.
Method: Individual patient data from six RCTs of depressed patients (total n = 2858) were used to estimate the
differential impact symptoms have on outcomes at three post intervention time points using individual items and
sum scores. Symptom networks (graphical Gaussian model) were estimated to explore the functional relations
among symptoms of depression and anxiety and compare networks for treatment remitters and those with
persistent symptoms to identify potential prognostic indicators.
Results: Item-level prediction performed similarly to sum scores when predicting outcomes at 3 to 4 months and 6
to 8 months, but outperformed sum scores for 9 to 12 months. Pessimism emerged as the most important
predictive symptom (relative to all other symptoms), across these time points. In the network structure at study
entry, symptoms clustered into physical symptoms, cognitive symptoms, and anxiety symptoms. Sadness,
pessimism, and indecision acted as bridges between communities, with sadness and failure/worthlessness being
the most central (i.e. interconnected) symptoms. Connectivity of networks at study entry did not differ for future
remitters vs. those with persistent symptoms.
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Conclusion: The relative importance of specific symptoms in association with outcomes and the interactions within
the network highlight the value of transdiagnostic assessment and formulation of symptoms to both treatment and
prognosis. We discuss the potential for complementary statistical approaches to improve our understanding of
psychopathology.
Keywords: Item level analysis, Network modelling, Comorbidity, Depression, Anxiety
Background
Psychological therapies and medication are effective
treatments for depression (e.g. [1, 2]). However, effect
sizes have been modest and gains in treatment outcomes
have plateaued [3]. Interventions for depression target a
broad range of symptoms, and knowledge of ‘what’ is be-
ing intervened upon is not necessary to the delivery of
most treatments, and poses problems for causal infer-
ence [4]. To improve interventions, we may need to im-
prove our knowledge of the structure of depression [5].
Depression is heterogeneous in terms of aetiology and
symptom profile [6–8]. Mood disorders are highly co-
morbid with anxiety disorders and may share psycho-
logical and biological vulnerabilities [9, 10]. The risk of
one disorder can increase the risk of another [11], and
the same end state may be achieved via many different
paths (equifinality) [12, 13]. These disorders are not
discrete entities and, as such, neglecting the symptom-
atic heterogeneity discards potential insights [14].
There is strong evidence that different symptoms are
not equivalent or interchangeable [15] and studies of in-
dividual symptoms in the last decade have brought im-
portant understanding. For example, individual
symptoms may differ in response to treatment [16, 17]
and have been shown to have a differential impact on
functioning [18–20]. Depression is a recurrent disorder
with the probability of relapse strongly associated with
the presence of residual depressive symptoms at the end
of treatment [21, 22]. Comorbid anxiety disorders are re-
lated both to worse treatment outcomes [23] and to an
increased risk of relapse [21]. An assumed unidimen-
sional view of depression, characterised by sum score
(sum of symptom severity scores) measurement and pre-
diction models, conceals the variability within depression
[24]. Understanding the relative importance of comorbid
symptoms may offer more information than severity of
disorder alone and provide additional treatment and
prognostic information [25]. Large-scale, multisite clin-
ical trial data, coupled with innovative statistical
methods, can provide categorisation and treatment opti-
misation to provide immediate benefits by informing
clinical decisions [26–28].
There is also value in studying the relations among
these symptoms. Network theory posits that the rela-
tionships between common affective, cognitive, and
somatic symptoms of these disorders may reflect poten-
tial causal pathways and elucidate maintenance mecha-
nisms [29]. Depression and anxiety have been modelled
as symptom networks using cross-sectional and longitu-
dinal data, demonstrating the interrelation between the
symptoms of each disorder, where comorbidity results
from mutually reinforcing interrelation between symp-
toms of each disorder [30, 31]. Anhedonia, anxiety,
worry, fatigue, and sadness are predominantly influential
symptoms in these networks [5, 32, 33]. The relationship
between symptoms/mechanisms can help to predict out-
come and potentially inform treatment targets and the
development of treatments targeting specific mecha-
nisms [34].
There are inconsistencies in the network literature ex-
ploring depression and anxiety, due to design, sampling,
and variability arising from differing measurement [15,
35]. When attempting to discriminate between groups
for the purposes of identifying whom may benefit from
treatment (prognosis at group level), there are varying
results from network comparison studies, where it has
been suggested that densely connected networks may be
less likely to recover [36]. However, these differences are
not always observed [37] and require large sample sizes
to detect any effect. It is also unclear how these net-
works generalise to idiographic networks at the present
stage. Past research has been conducted on small sam-
ples with low quality assessment of patients (or non-
clinical samples) and lack of adequate consideration of
comorbidity (missing out on the wider spectrum of anx-
iety disorders).
In this study we aim to:
1) Identify important symptoms for outcome by
examining the (differential) impact of individual
symptoms on prognosis for adults with depression
that took part in randomised controlled trials after
seeking treatment in primary care and assess
whether individual symptoms offer predictive value
above sum scores.
2) Discern the functional relations among symptoms
and clarify the interplay between highly comorbid
symptoms of depression and anxiety disorders.
3) Consider whether there are differences in the
baseline symptom networks of patients that
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Data were drawn from a subset of the Dep-GP individual
patient data (IPD) database [36]. The formation of the
Dep-GP IPD dataset has been described elsewhere [36].
Bibliographic databases were searched up to 29 April
2020 for RCTs of unipolar depressed adults seeking
treatment for depression or with depressive symptoms
significant enough for them to seek treatment, recruited
from primary care; had at least one active treatment
arm; and used the CIS-R at baseline.
Studies were excluded if they were studies of patients
with depression secondary to a diagnosis of personality
disorder, psychotic conditions, or neurological condi-
tions; bi-polar or psychotic depressions; children or ado-
lescents; feasibility studies; or were studies of adults with
either depression or an anxiety disorder, rather than a
primary depression with or without comorbid anxiety.
Additional inclusion criteria for the present study were
the use of the Beck Depression Inventory (2nd Edition)
(BDI-II) [37] at study entry. The inclusion criteria en-
sured uniformity in the measurement of depressive and
anxiety symptoms, chronicity of problems, and deter-
mination of diagnoses including anxiety comorbidities.
Data on all individual patients from all six eligible
RCTs were included in the current study, these were
COBALT [38], GENPOD [39], PANDA [40], TREAD
[41], MIR [42], and IPCRESS [43].
Measures
Individual items from the BDI-II [37], and individual
symptom subscales of the CIS-R [44], including duration
of depression and anxiety, which have been shown to be
independently associated with prognosis for depressed
adults [45].
Outcomes
The primary outcome was endpoint depressive symp-
toms at three to four months post-study entry. Five of
the studies used the BDI-II at 3–4 months, and one used
the PHQ-9. A continuous ‘depression severity’ score was
developed by converting the responses on each measure
to a latent trait depressive symptom severity score (PRO-
MIS T-Score) [46], using the expected a posteriori par-
ameter from a multidimensional item-response theory
based score conversion tool [47]. Depressive symptoms
(PROMIS T-Score) at 6–8 months post-study entry, and
9–12 months were secondary outcomes.
As a sensitivity analysis, the BDI-II scores were used
as outcomes for the three time points (five studies at 3–
4months; four studies at 6–8months, and three studies
at 9–12 months).
Data analysis
All analyses were performed in R 3.6 [48] and Stata 16.0
[49]. Analysis code is available from https://osf.io/wck6
b/. The data that support the findings of this study are
available from the lead author of the Dep-GP (JB) sub-
ject to agreement from the chief investigators or data
controllers of the individual RCTs. Restrictions apply to
the availability of these data, which were used under li-
cence for this study.
Pre-processing
Datasets were combined and pre-processed together.
There was no missing data at study entry. All items were
investigated to ensure they met assumptions for inclu-
sion in the network models, including assessing for near
zero variance, roughly equal variance of items, asymmet-
rical distributions, and topological overlap [50]. Items
were removed if they violated assumptions across all
studies. We aimed to address topological overlap using
the ‘goldbricker’ function in R [51] with a threshold of
25% (correlations between items should have signifi-
cantly different correlations with 25% of the other
items), accepting minimal correlation of 0.5.The respect-
ive pair of items were combined into a single variable
using principal component analysis (PCA) if reasonable
to combine from a clinical perspective. Items were after-
wards rescaled to their original Likert scale values to
make variances comparable across items [52].
Association with outcomes
We aimed to examine the differential impact of individ-
ual symptoms on outcomes and assess whether individ-
ual symptoms offer predictive value above sum scores.
Sum score totals were entered into a linear regression
model, while the item severity scores were entered into
an elastic net generalised linear model (ENR) [53]. ENR,
a statistical method combining lasso and ridge regression
approaches, minimises overfitting and the use of ten sep-
arate, tenfold repeated cross validation aids in assessing
the effectiveness of the model. The item-level and sum-
score models were compared using root mean squared
error, mean absolute error, and R2.
As the item-level predictors were assumed to be corre-
lated and that we wished to assess the explanatory power
of individual predictors, we estimated the contribution
of each item to the outcome prediction using Shapley
Additive exPlanations [54], following ENR model estima-
tion. Five hundred Monte Carlo repetitions were used to
estimate each Shapley value. This metric is more accur-
ate than other variable importance metrics when predic-
tors are dependent [55]. Items with large Shapley values
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are ‘important’, indicating the relative contribution of an
item to the model while accounting for correlated fea-
tures in the data.
Network modelling
A graphical Gaussian model (GGM) aims to capture
the direct effects (edges) between items while control-
ling for all other items in the network. A network
was estimated by combining data from the six RCTs.
The sample was then split into two networks (those
with persistent symptoms vs. remitters: BDI-II score
< 10 at 3–4 months); the networks were re-estimated
and compared using the network comparison test
with 1000 iterations [56].
We performed a number of analyses to test the robust-
ness of the networks we estimated.
While lasso [57], regularised GGMs [58] are most fre-
quently reported in the network literature, lasso specifi-
city has recently been shown to be lower than expected
in dense networks with many small edges, leading to an
increase in false positives [59]. We also estimated an
unregularized GGM using an iterative modelling proced-
ure: the Extended Bayesian Information Criterion
(EBIC). Selecting unregularized GGMs according to
EBIC has been shown to converge to the true model
[60]. The algorithm runs 100 glasso models, re-fits all
models without regularisation,, and subsequently adds
and removes edges until EBIC can no longer be im-
proved. The best performing model (EBIC parameter)
was selected to provide a conservative GGM estimation
(high specificity).
Chronicity of disorders has been shown to interact
with symptom severity [45, 61]. We corrected for the
potential confounding effects of duration of depression
and anxiety within the network models.
Combining data obtained from different studies holds
the potential for between-study differences to influence
estimation. A network estimation procedure (fused
graphical lasso: FGL) [62] has been designed to manage
this issue, however, this involves estimating networks in-
dividually and penalising between study differences.
Where study size affects the estimation of edges, this
can lead to penalization based on sample size rather
than on true differences between the network structures
[63]. As such, it was decided to estimate based on the
combined sample and to compare this to the FGL net-
work (joint estimation using a fused penalty, and 10-fold
cross validation), to assess the potential influence of
group level differences.
Finally, the network model was tested for the stability
of expected influence centrality and the accuracy of in-
terrelations using a nonparametric bootstrapping pro-
cedure (1000 iterations) [64]. For details of these, see the
Supplementary material.
We obtained two types of information from the result-
ing network structures. First, symptoms can form clus-
ters or communities with other symptoms to which they
are connected reflecting commonalities between them.
We estimated the community structure by using a boot-
strapped walktrap algorithm [65], investigated for item
stability before selecting communities. Second, the over-
all connectivity of a symptom, i.e. its connection to other
symptoms, can be quantified in a number of ways and is
referred to as centrality. Some scholars have argued that
activation of a central symptom has the potential to acti-
vate associated symptoms in the network [66], where
symptom centrality is then interpreted as symptom im-
portance, given that identifying such symptoms may
have the potential to elucidate the processes underlying
comorbidity and implications for treatment. Within the
context of communities specifically, symptoms which
connected to more than one community are referred to
as bridge symptoms. Within cross-sectional networks (as
explored here), we refer to centrality as a statistical par-
ameter, i.e. the strength of predictive associations be-
tween symptoms. Centrality does not automatically
translate into clinical relevance [67] and cautious inter-
pretation is warranted [63]. It requires consideration of
how the symptoms activate within the network (flow or
transfer), the conceptual similarity between symptoms,
and whether there is missing information on the shared
variance [68]. Symptom centrality was calculated using
expected influence (EI: strength of the relationships a
given node has with other node) and the geometric
mean of the participation ratio (PR) and participation
coefficient (PC), and normalised bridge expected influ-
ence centrality [69]. The PR quantifies the number and
strength of edges, while the PC takes the community
structure into account [70].
Results
Demographic details for the studies are presented in
Table 1. Overall samples were comparable. The severity
of depressive symptoms captured by BDI-II scores at
baseline in the PANDA sample was lower than the other
trials. Descriptive results are reported in the supplemen-
tary materials.
Association with outcomes
In order to assess the utility of item level models, we
compared them to sum score models. For all item level
models (Table 2), the optimal shrinkage parameters for
the elastic net regression model were selected via mini-
mum cross-validated error criterion ( = 0.1 and λ =
0.05). While models performed similarly at 3–4 months
and 6–8 months, the item level elastic net regression
model outperformed linear regression with BDI-II and
CIS-R (sum of anxiety items) totals at the 9–12-month
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time point. The sensitivity analysis performed similarly.
Due to the absence of two studies (IPCRESS and PAND
A) at the 9–12-month endpoint, we reran the analyses
for the earlier time points without these studies. This
sensitivity analysis did not reveal any difference in the
pattern of model performance.
Pessimism (Fig. 1) was consistently the most important
item; health anxiety was in the upper quartile at each time
point; and concentration, failure/worthlessness, also in the
upper quartile at 3–4months; guilt and sleep at 6–
8 months; and somatic symptoms at 9–12 months.
Network modelling
For the individual items in the network model, near zero
variance (e.g. due to floor and ceiling effects) was not
observed. However, we saw asymmetric distributions
(skew) on a number of items. As such, a Spearman co-
variance matrix was estimated and used to estimate the
network model. Multi-collinearity was identified for two
pairs of items (loss of pleasure with loss of interest, fail-
ure with worthlessness). New items were constructed
using PCA for each pair. The optimal model for the net-
work analysis was an unregularized graphical Gaussian
model using the EBIC.
A walktrap algorithm identified three, stable, symptom
communities (median = 3, SD = 0.15, 95% CI [2.71,
3.29]). The three communities split into anxiety items,
depressive cognitions and depressive physical symptoms.
Bridging EI elucidated three bridging symptoms between
the communities: sadness and indecisiveness (from the
Table 1 Descriptive table of studies included in the dataset. Summary of included variables provided in supplementary materials. *
International Baccalaureate equivalent ** High school diploma equivalent
COBALT GENPOD IPCRESS MIR PANDA TREAD Overall
(N = 469) (N = 601) (N = 295) (N = 480) (N = 652) (N = 361) (N = 2858)
Baseline BDI-II total
Mean (SD) 31.8 (10.7) 33.7 (9.67) 33.2 (8.80) 31.1 (9.91) 23.9 (10.3) 32.1 (9.24) 30.4 (10.5)
Median [min, max] 30.0 [14.0, 60.0] 33.0 [15.0, 60.0] 33.0 [15.0, 58.0] 30.0 [14.0, 58.0] 23.0 [2.00, 54.0] 31.0 [14.0, 57.0] 30.0 [2.00, 60.0]
Gender
Female 339 (72.3%) 408 (67.9%) 200 (67.8%) 332 (69.2%) 384 (58.9%) 239 (66.2%) 1902 (66.6%)
Male 130 (27.7%) 193 (32.1%) 95 (32.2%) 148 (30.8%) 268 (41.1%) 122 (33.8%) 956 (33.4%)
Age
Mean (SD) 49.6 (11.7) 38.8 (12.4) 34.9 (11.6) 50.7 (13.2) 39.7 (15.0) 39.8 (12.6) 42.5 (14.1)
Median [min, max] 50.0 [18.0, 74.0] 38.0 [18.0, 74.0] 34.0 [18.8, 74.6] 51.0 [19.0, 84.0] 38.5 [18.0, 73.0] 39.0 [18.0, 69.0] 42.0 [18.0, 84.0]
Employment status
Employed 206 (43.9%) 357 (59.4%) 178 (60.3%) 237 (49.4%) 433 (66.4%) 230 (63.7%) 1641 (57.4%)
Seeking employment 151 (32.2%) 123 (20.5%) 35 (11.9%) 102 (21.2%) 73 (11.2%) 48 (13.3%) 532 (18.6%)
Not seeking employment 112 (23.9%) 121 (20.1%) 82 (27.8%) 141 (29.4%) 146 (22.4%) 83 (23.0%) 685 (24.0%)
Education
Degree or higher 95 (20.3%) 0 (0%) 102 (34.6%) 95 (19.8%) 230 (35.3%) 87 (24.1%) 609 (21.3%)
A-level or diplomas* 123 (26.2%) 0 (0%) 88 (29.8%) 135 (28.1%) 220 (33.7%) 104 (28.8%) 670 (23.4%)
GCSE** 131 (27.9%) 0 (0%) 62 (21.0%) 150 (31.2%) 145 (22.2%) 102 (28.3%) 590 (20.6%)
None or other 120 (25.6%) 0 (0%) 43 (14.6%) 100 (20.8%) 57 (8.7%) 68 (18.8%) 388 (13.6%)
Missing 0 (0%) 601 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 601 (21.0%)
Ethnicity
White 459 (97.9%) 575 (95.7%) 281 (95.3%) 469 (97.7%) 579 (88.8%) 336 (93.1%) 2699 (94.4%)
Non-White 10 (2.1%) 26 (4.3%) 14 (4.7%) 11 (2.3%) 73 (11.2%) 25 (6.9%) 159 (5.6%)
Diagnoses
Number of comorbid diagnoses 2.40 (1.09) 2.39 (0.92) 2.32 (0.99) 2.10 (0.97) 1.43 (1.18) 2.20 (1.17) 2.09 (1.12)
Generalised anxiety disorder 312 (66.52%) 410 (68.22%) 186 (63.05%) 219 (45.63%) 299 (45.86%) 238 (65.93%) 1664 (58.2%)
OCD 79 (16.84%) 114 (18.97%) 62 (21.02%) 62 (12.92%) 52 (7.98%) 50 (13.85%) 419 (14.7%)
Panic disorder 67 (14.29%) 51 (8.49%) 16 (5.42%) 45 (9.38%) 42 (6.44%) 14 (3.88%) 235 (8.2%)
Agoraphobia 61 (13.01%) 75 (12.48%) 28 (9.49%) 81 (16.88%) 42 (6.44%) 35 (9.70%) 322 (11.3%)
Social phobia 64 (13.65%) 64 (10.65%) 44 (14.92%) 58 (12.08%) 68 (10.43%) 52 (14.40%) 350 (12.2%)
Specific phobias 91 (19.40%) 127 (21.13%) 46 (15.59%) 62 (12.92%) 98 (15.03%) 61 (16.90%) 485 (17%)
Chronic fatigue syndrome 343 (73.13%) 476 (79.20%) 220 (74.58%) 311 (64.79%) 288 (44.17%) 257 (71.19%) 1895 (66.3%)
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physical symptoms community) and pessimism (cogni-
tive symptoms community).
Centrality estimates (i.e. measures of the strength of
connection to other items) are reported in Fig. 2. The EI
correlation stability coefficient was high (0.75), suggest-
ing that the ordering of items based on centrality
remained the same after re-estimating the network with
fewer cases (the probability the correlation between ori-
ginal centrality indices and centrality of networks based
on subsets was 0.7 or higher) and can be reliably
interpreted.
The estimates from the different metrics (EI and PC/
PR) were correlated (r = 0.58). The most central symp-
toms were sadness (PC/PR) and failure/worthlessness
(EI). Failure/worthlessness had a significantly higher EI
centrality than twenty-one other symptoms (see supple-
mentary material). The next most central nodes (EI)
were sadness, self-criticism, and loss of energy (all z-
score > 1), followed by concentration, loss of pleasure/
interest, and fatigue (z-score > 0.96), while the next most
central nodes when using PC/PR were pessimism, fail-
ure/worthlessness, and punishment (all z-score > 1), then
guilt, indecisiveness, and suicidal thoughts (all z-score >
0.80). Notably, while suicidal thoughts were highly cen-
tral according the PC/PR metric (z-score = 0.80), it was
much less central using EI (z-score = − 0.67). Loss of en-
ergy displayed the opposite relationship, more central
for EI (z-score = 1.01) than PC/PR (z-score = − 2.03).
Table 2 Performance of the regression models. Sum scores:
BDI-II and CIS-R; RMSE root mean squared error; MAE mean
absolute error; R2 proportion of the variance explained
PROMIS T-score
RMSE R2 MAE
3 to 4 months
N = 2646
Items 0.925 0.146 0.73
Sum scores 0.926 0.143 0.73
6 to 8 months
N = 1297
Items 0.926 0.147 0.734
Sum scores 0.924 0.146 0.735
9 to 12 months
N = 1110
Items 0.919 0.161 0.744
Sum scores 0.935 0.126 0.753
Fig. 1 Shapley values for variable importance are plotted: (showing the difference contribution of items to predictions)
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Fig. 2 Network plot (top) with communities. Bridge symptoms are categorised separately; however, sadness and indecisiveness fall into
community 1, and pessimism into community 3. The thickness of the edges indicates to what degree items are related, and the colour of the
edges indicates the relationship sign (i.e. positive = blue, negative = red). Centrality estimates: PC/PR and EI (bottom)
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Loss of energy and obsessions were jointly the least cen-
tral nodes using PC/PR, and obsessions was also the
least central when using EI.
Robustness checks suggest the resulting graphical
Gaussian model was stable and accurate. Stability and
accuracy plots, individual networks (with the fused pen-
alty) and the fused network model are supplied in the
supplementary materials. Mean severity was not signifi-
cantly correlated (p < 0.05) with EI (r = 0.21) or PC/PR
(r = − 0.05), while the standard deviation was signifi-
cantly correlated for both EI (r = − 0.56) and PC/PR (r =
− 0.41). Symptom severity was not associated with nodes
being interconnected. Lower variability was associated
with variability, which is the reverse of a more typical
concern: differential variability driving the centrality of
nodes [52].
The interrelation of the network and the FGL network
were compared (r = 0.72), suggesting that between study
differences had a small effect on network estimation.
The network was corrected for the influence of duration
of depression and anxiety; however, the overall influence
on edge estimation was negligible (interrelation between
the corrected network and a network estimated without
duration variables: r = 0.997). Overall, the resulting net-
work model can be considered robust.
Network comparison test
Networks (unregularized) were compared (1000 itera-
tions) for those who were classified as in remission (n =
956) and those who were not (n = 1466). Mean severity
differences at baseline were significant for all items (p <
0.001). The correlation between networks was high (r =
0.67). While there were significant difference between
edges, the overall networks (see supplementary material)
did not differ in connectivity (global strength invariance:
p < 0.08) and post hoc tests were not warranted. There
was only evidence of one difference in centrality between
the networks: somatic symptoms were more connected
in the remitter network than the persister network (p <
0.001).
Discussion
Individuals with depression also present with comorbid-
ity, and this could present an issue for depression treat-
ment. Understanding how symptoms influence one
another across traditional diagnostic boundaries, and
how they influence important outcomes, may provide in-
sights relevant to the assessment and treatment of mood
disorders. In this study, we initially examined the differ-
ential impact of individual symptoms on prognosis and
assessed whether individual symptoms offer predictive
value above sum scores. The item level models of out-
comes post-treatment and the sum score models were
similarly associated with outcomes at 3–4 and 6–
8 months but explained considerably more variance at
9–12 months. Pessimism was consistently the most im-
portant predictor of future outcomes (independent of its
mean), indicating that experiencing pessimism rather
than severity of the symptom is responsible for this asso-
ciation. Secondly, we explored the functional relations
among comorbid symptoms of depression and anxiety
disorders using network analysis. The symptom network
comprised of three communities clearly clustering into
anxiety items, depressive cognitions, and depressive
physical symptoms. The primary bridge symptoms be-
tween communities were sadness; pessimism; and in-
decision. The most central symptoms across both
centrality metrics were sadness and failure/worthless. Fi-
nally, we analysed differences in the symptom networks
at study entry for patients that remitted vs. those whose
depression persisted, after treatment. Network compari-
son revealed no overall differences in connectivity. To-
gether, the present findings suggest the utility of item-
level analysis in informing the content of assessments
and consideration of individual items over and above
scale scores when predicting prognosis.
Findings in context
Exploring the associations with treatment outcomes re-
vealed that item-level prediction methods performed
similarly to sum scores and outperformed sum score
models at the 9–12-month endpoint. It is not clear why
there is a difference at this time point; while it was not
due to attrition between endpoints, it could be due to
random variation. It may also reflect the course of de-
pression following intervention, or the cyclical nature of
depression such that individual items are better at pre-
dicting the relapse or maintenance of symptoms after
benefits of treatment have faded, or where an amelior-
ation of symptoms occurred due to further treatment
post randomisation. There is an ongoing debate in the
field whether central items derived from network models
offer predictive utility beyond other items [71–73]. Pes-
simism was not only the best predictor across outcomes;
it was a central item (ranked 2nd on PC/PR and 6th on
EI centrality) that acted as a bridge between communi-
ties and showed strong associations with sadness and
failure/worthlessness. Sadness, comparatively, did not
predict well across time points. It is worth noting that
sadness falls within the physical symptom community
and pessimism within the cognitive community. The
amenability to act on an emotion (sadness) is under-
standably less than that of a cognition (pessimism), a
target of cognitive therapy, while pessimism in associ-
ation with a sense of failure/worthlessness may nega-
tively impact treatment engagement (i.e. the motivation
to sustain goal pursuit in the face of obstacles) [74].
Given the central role and prognostic value of
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pessimism, we might speculate that it is associated with
treatment factors, where pessimism hinders some people
making progress and may not be directly addressed by
some psychological treatments.
Symptoms of anxiety and depression clustered into
separate communities with certain symptoms acting as
bridges between communities. The bridge symptoms are
statistically relevant and theoretically linked: indecision
is a symptom in the classifications of both depression
and generalised anxiety disorder, pessimism overlaps
with worry [75] and the strong cross-community edge of
sadness to worry was similar to findings in other studies
[32, 76]. The results therefore provide evidence that
these bridging symptoms may be important in the emer-
gence of comorbidity between anxiety disorders and
depression.
Planned comparisons of networks at study entry for
those whose depression would persist versus those who
would be in remission revealed no overall difference in
connectivity, in contrast to Van Borkulo et al. [77], but
similar to Schweren et al. [78].
Overall, we found no correlation between centrality
metrics and Shapley values. This extends prior work on
the association between centrality and the prognostic
utility of items [71]. Failure/worthlessness was predict-
ively important at 3–4 months, displayed high centrality
and is suggested to be a key symptom in depression and
anxiety [30]. The predictive utility of health anxiety and
somatic concerns may be considered alongside the ob-
servation from the network comparison where there was
a difference in centrality with somatic concerns more
connected in the remitter network. Health anxiety was
in the upper quintile of variable importance across time
points, but relatively unimportant in terms of centrality.
Not surprisingly, given the conceptual overlap, with
health anxiety, the strongest edge was with somatic con-
cerns. As such, the degree of concern for one’s health, or
attention to somatic symptoms, whilst not playing a sig-
nificant role within the maintenance of depression, may
act as a motivational spur to engage with treatment (in
this way enabling rather than disabling the individual).
The absence of this anxiety may reflect an apathy about
one’s health which is not captured by the motivational
item in the BDI. While the predictive modelling did con-
sider the influence of each item independent of the other
items, modelling the predictive value of individual items
may be improved by examining the association between
the changes at symptom level and the overall network
[79, 80].
The network derived in this study provides empirical
phenomena that can be explained by principles of net-
work theory. This requires interpreting the network as a
causal system, even though we cannot infer temporal re-
lationship between symptoms and there is an absence of
causal mechanisms within the external field (e.g. envir-
onmental factors) [29]. These limitations apply to most
of the findings in the network literature, although over-
interpretation is common [81]. Holding this in mind, we
can consider possible pathways and mediating role of
symptoms through the network. For example, taking sui-
cidal ideation as a clinically severe symptom, we can
identify the shortest path from worry [82] passing
through sadness (bridge), and from loss of pleasure/
interest [83] to suicidal thoughts, passed through pes-
simism (bridge). It is possible that any causal effect be-
tween these connections may be part of a longer
pathway within the network highlighting a need for
greater attention to be given to symptom interactions.
The statistical model investigates a symptom level,
transdiagnostic conceptualization of the symptom inter-
actions for individuals diagnosed with depression partici-
pating in RCTs. These interventions are based on
biological or psychological theories, most notably Beck’s
cognitive of theory of depression [84]. Clinically, prag-
matism trumps theoretical completeness; simple inter-
ventions which achieve rapid change do not require a
detailed appreciation of the potential underlying mecha-
nisms. However, oversimplified theories may restrict the
ability to identify causal patterns, and gaps emerge in
practice where the model is suggested to not fit the pa-
tient [85]. More process-driven interventions targeting
shared features of disorders have been developed [86,
87], yet there is no unifying theory. The findings pre-
sented may help bridge the gap between disorder-
specific theories and more transdiagnostic theories. Con-
sidering how symptoms may interact can help clinicians
and researchers to understand underlying processes and
in turn to conceptualise their patients’ difficulties in a
way that supplements existing knowledge. A functional
analysis which integrates the association between sad-
ness and worry does not need to conceptualise the indi-
vidual as having two disorders, but can consider how,
for the individual, this interaction is being fuelled and
may be contributing to their distress.
The journey to develop models that provide both
explanatory and predictive utility will lead to greater
understanding of psychopathology [88]. While the
analysis presented is primarily exploratory, it sets up
clear testable hypotheses. These can be derived by
examining the central structures within the network,
formulating hypotheses and testing on an independent
sample [89]. For instance, whether the bridge edges
belonging to pessimism, sadness, and indecisiveness
re-emerge in an independent sample or whether a
discrete intervention targeting pessimism would alter
the network structure and lead to improved outcome.
These statistical methods may help inform how iden-
tifying pathways and targets may lead to improved
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treatments all dependent on better assessment of
symptoms.
Strengths and limitations
This study has clear strengths, making use of a large
sample of individuals participating in RCTs for depres-
sion in primary care. The use of same assessment mea-
sures at study entry removed the need to harmonise
data across different measures for the network. While
this is less true of outcomes where issues of measure-
ment errors arise from the use of PROMIS T-Score, the
sensitivity analyses provided confidence in the results.
The demographic balance across samples may affect
generalisability; however, five of the six trials were prag-
matic trials more closely representative of patient popu-
lations. Most cases of depression are treated in primary
care, and the studies being set in primary care, improve
the potential generalisability to patients seen in this set-
ting [90].
This study was limited to the use of aggregate/group
level findings to inform within person processes. How-
ever, the presence of an RCT outcome variable affords
us the ability to detect changes from one state (e.g. de-
pressed) to another (e.g. remitted), which is typically not
the case with idiographic research studies that collect
cross-sectional data. Exploring the prognostics value of
networks on deterioration of symptoms would extend
the utility of network analysis. This would however re-
quire generating idiographic networks, where reliable es-
timation necessitates many time points (low sensitivity
at 100 time points [91].
The accuracy of the network is limited by the items in-
cluded and those omitted. The network does not cover
the breadth of comorbidity of symptoms across psycho-
pathology and is missing other environmental variables.
Social adversity is associated with worse treatment out-
comes for some patients with depression; it can be im-
portant to assess for and address these issues in clinic,
where possible, to mitigate the risks of poor prognoses
[92]. There is also the possibility that the centrality of
sadness particularly represents a strong association with
a latent variable rather than a specific role within the
network [93].
The network models adjusted for duration of depres-
sion and anxiety, and a sensitivity analysis assessed for
the influence of between study variability, adding robust-
ness to the findings. While RCTs are used in the ana-
lysis, treatment arms were not factored in and treated as
equivalent when estimating outcome. This may make
the findings generalizable where findings are applicable
regardless of treatment offered especially as the treat-
ments included reflect those commonly available in pri-
mary care. Controlling for treatment group within the
outcome modelling and controlling for relevant
covariates (e.g. age, gender and social economic status)
would also have improved the robustness of the findings.
Such adjustments would have been fitting where the em-
phasis was on developing the best predictive model, in-
stead of comparing the predictive ability of symptoms
vs. total scores. More comprehensive prediction model-
ling using the Dep-GP dataset has been conducted [94].
Additionally, our modelling did not include train/test
split, as the whole sample was used in estimation of the
network models. While a true out-of-sample ‘holdout’
dataset would have provided an unbiased evaluation of
model fit, and is the preferred method for evaluating
such models [95], the internal cross-fold validation
employed in the symptom level model offers a layer of
robustness supporting the final model estimates (where
overfitting presents an issue). This study focussed on
item-level analysis in comparison to sum-scores, future
comparisons with models which may measure latent
constructs in other ways, could be informative.
Single item symptom measurement will have unknown
reliability and construct validity. Equally, the restricted
range (e.g. a four-point scale) may not adequately cap-
ture the range of symptom variance occurring in the
sample. Symptom measurement on a broader scale may
improve the prediction of changes over time.
Conclusions
Our study used samples from high-quality randomised
controlled trials, and the findings can be generalised to
adults with depression being treated in primary care.
This study has reiterated the importance of assessing for
both depressive and anxious symptoms among adults
seeking treatment for depression, and that valuable in-
formation about prognosis can be gained by understand-
ing the interrelations between individual symptoms,
information which is not available when considering
sum scores or baseline symptom severity alone. This
may be particularly important to longer term outcomes
from treatment. Treatment selection and application is
often hampered by comorbid symptoms and considered
to introduce ‘complexity’ [96]. Considering the bidirec-
tional relationship between symptoms and associations
which may be mediated by another symptom (e.g. a
bridge symptom) may help to consider comorbidity as
normative.
While specific symptoms and associations have been
highlighted, the aim is not to offer simple heuristics to
inform clinical judgement and decision making. The
relative importance of the highlighted associations
should not be overweighed. The aim is not to identify
individual items, but to consider the network of interac-
tions. The critical role of individual symptoms and their
interactions give rise to the activation of the network
through pathways and anxiety and depressive cognitive
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and physical symptoms may activate one another via
these pathways. This network highlights how symptoms
of depression and anxiety disorders influence one an-
other. Clinically, there is a need for treatments to ad-
equately assess and address comorbidity.
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